Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients

Critically ill COVID-19 and non-COVID-19 patients receive thromboprophylaxis with the LMWH nadroparin. Whether a standard dosage is adequate in attaining the target anti-FXa levels (0.20 –0.50 IU/ml) in these g...

Source: BMC Clinical Pharmacology - February 6, 2024 Category: Drugs & Pharmacology Authors: Monique M.R. de Maat, Henk J. van Leeuwen, Lian Roovers, Sabine J.G.M. Ahlers, Jolanda Lambers and Marcel M.C. Hovens Tags: Research Source Type: research